SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, today announced participation at several upcoming investor conferences.
Details of each presentation are as follows:
Cowen 2nd Annual Genetic Medicines Summit
Panel: Gene Therapies - Clinical Topics
Date: Thursday, February 3, 2022
Time: 12:00 p.m. ET
SVB Leerink Global Healthcare Conference
Date: Friday, February 18, 2022
Time: 3:40 p.m. ET
Cowen 42nd Annual Health Care Conference
Panel: Gene Therapy
Date: Wednesday March 9, 2022
Time: 12:50 p.m. ET
About Tenaya Therapeutics
Tenaya Therapeutics is a biotechnology company committed to a bold mission: to discover, develop and deliver curative therapies that address the underlying drivers of heart disease. Founded by leading cardiovascular scientists from Gladstone Institutes and the University of Texas Southwestern Medical Center, Tenaya is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. For more information, visit www.tenayatherapeutics.com.